What is Fertility Drugs Market?
One of the most significant medical advancements of the mid-20th century may have been the development of fertility drugs. The rise in the demand for increasing the chances of conceiving and carrying the baby to is booming the market demand as these medicines have made it possible for countless people to fulfill their dream of becoming parents. Fertility drugs are the main course of treatment for women who are infertile due to ovulation disorders such as irregular menstrual cycles. According to the research, done by the American Society for Reproductive Medicine (ASRM), about 25 percent of infertile women have problems with ovulation.
The market study is being classified by Type (Prescription Fertility Drugs and Over-The-Counter Fertility drugs), by Application (Fertility Centers, Hospitals & Surgical Clinics, Cryobanks and Research Institutes) and major geographies with country level break-up.
Merck & Co. (United States), Ferring Pharmaceuticals (Switzerland), Bayer (Germany), Berlex Laboratories Inc. (United States), Janssen Pharmaceutical Inc. (United States), Pfizer (United States), Novartis AG (Switzerland), Procter & Gamble Pharmaceutical (United States), Sanofi S.A (France) and Eli Lilly and Co.(United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Livzon Pharmaceutical Group Co., Ltd.(China).
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Fertility Drugs market throughout the predicted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Fertility Drugs market by Type, Application and Region.
On the basis of geography, the market of Fertility Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Increasing Number of Fertility Clinics Worldwide
- The rising cases of infertility across the globe are increasing the demand for fertility drugs
Restraints
- Risks of ovarian tumors
- Risks and side effects of fertility drugs
- Stringent government regulations
Opportunities
- Increasing Use of Fertility Treatment Options By Single Parents and Same-Sex Couples
Challenges
- Reduced Efficacy Among Older Women
- The side effects caused due to fertility drugs restricted the growth of the fertility drugs
In December 2019 Mankind Pharma Launches Infertility Drug named Dydroboon launching this drug company to rank the first Indian and second global firm to develop drugs. It is a safe and effective drug as other drugs.
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Fertility Drugs Manufacturer, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry